Could Recent Decreases in Breast Cancer Incidence Really Be Due to Lower HRT Use? Trends in Attributable Risk for Modifiable Breast Cancer Risk Factors in Canadian Women

Overview

Journal Can J Public Health

Publisher Springer Nature

Specialty Public Health

Date 2011 Jan 11

PMID 21214057

Citations 9

Authors

C Ineke Neutel

Howard Morrison

Affiliations

Soon will be listed here.

Abstract

Objectives: Recent downward trends in breast cancer incidence have been attributed to declining use of hormone replacement therapy (HRT). To determine whether this is a credible conclusion, this study calculated population attributable risk (PAR) for HRT and other modifiable breast cancer risk factors.

Methods: PAR calculation needs both the prevalence of a risk factor, and the relative risk (RR) for breast cancer incidence for that risk factor. Prevalences were calculated for Canadian women, aged 50-69, participating in the National Population Health Survey, 1994-2006. RR were derived from published research: 1.4 for HRT use, 1.4 for excessive alcohol use, 1.15 for physical inactivity, 1.25 for smoking, 1.4 for BMI over 30 kg/m2. Trends for PAR were calculated for the risk factors separately, as well as combined. Age-adjusted breast cancer incidence rates were calculated for Canadian women aged 50-69 for the years 1994-2004.

Results: Between 1998 and 2004, PAR for HRT decreased by 50%. PAR for other risk factors showed only small changes, and the combined PAR decreased by 18.6%. Age-adjusted breast cancer incidence for women aged 50-69 peaked in 2000 at 330.0/100,000, then dropped by 17.2% by 2004.

Conclusion: Patterns of PAR for HRT use in Canada are consistent with the noticeable decrease in breast cancer incidence observed for women of the same age group. Combining PAR for all risk factors indicated that changes in HRT use overpowered any trends of other risk factors. The combined PAR suggest that alterations in lifestyle could have considerable impact on breast cancer incidence.

Citing Articles

Effect of alcohol consumption on breast cancer: probabilistic bias analysis for adjustment of exposure misclassification bias and confounders.

Pakzad R, Nedjat S, Salehiniya H, Mansournia N, Etminan M, Nazemipour M BMC Med Res Methodol. 2023; 23(1):157.

PMID: 37403100 PMC: 10318777. DOI: 10.1186/s12874-023-01978-6.

Effect of Smoking on Breast Cancer by Adjusting for Smoking Misclassification Bias and Confounders Using a Probabilistic Bias Analysis Method.

Pakzad R, Nedjat S, Yaseri M, Salehiniya H, Mansournia N, Nazemipour M Clin Epidemiol. 2020; 12:557-568.

PMID: 32547245 PMC: 7266328. DOI: 10.2147/CLEP.S252025.

The Combined Association of Modifiable Risk Factors with Breast Cancer Risk in the Women's Health Initiative.

Arthur R, Wassertheil-Smoller S, Manson J, Luo J, Snetselaar L, Hastert T Cancer Prev Res (Phila). 2018; 11(6):317-326.

PMID: 29483073 PMC: 6866659. DOI: 10.1158/1940-6207.CAPR-17-0347.

Cancer incidence attributable to excess body weight in Alberta in 2012.

Brenner D, Poirier A, Grundy A, Khandwala F, McFadden A, Friedenreich C CMAJ Open. 2017; 5(2):E330-E336.

PMID: 28455439 PMC: 5510285. DOI: 10.9778/cmajo.20160039.

Cancer incidence attributable to the use of oral contraceptives and hormone therapy in Alberta in 2012.

Grevers X, Grundy A, Poirier A, Khandwala F, Feldman M, Friedenreich C CMAJ Open. 2016; 4(4):E754-E759.

PMID: 28018891 PMC: 5173458. DOI: 10.9778/cmajo.20160046.

References

Ravdin P, Cronin K, Howlader N, Berg C, Chlebowski R, Feuer E . The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007; 356(16):1670-4. DOI: 10.1056/NEJMsr070105. View

Johnson K, Miller A, Collishaw N, Palmer J, Hammond S, Salmon A . Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009). Tob Control. 2010; 20(1):e2. DOI: 10.1136/tc.2010.035931. View

Bruzzi P, Green S, Byar D, Brinton L, Schairer C . Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol. 1985; 122(5):904-14. DOI: 10.1093/oxfordjournals.aje.a114174. View

Clarke C, Glaser S . Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control. 2007; 18(8):847-52. DOI: 10.1007/s10552-007-9029-1. View

Coombs N, Taylor R, Wilcken N, Boyages J . HRT and breast cancer: impact on population risk and incidence. Eur J Cancer. 2005; 41(12):1775-81. DOI: 10.1016/j.ejca.2005.03.030. View

Rosano G, Panina G . Cardiovascular pharmacology of hormone replacement therapy. Drugs Aging. 1999; 15(3):219-34. DOI: 10.2165/00002512-199915030-00005. View

Canfell K, Banks E, Moa A, Beral V . Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust. 2008; 188(11):641-4. DOI: 10.5694/j.1326-5377.2008.tb01821.x. View

Lahmann P, Friedenreich C, Schuit A, Salvini S, Allen N, Key T . Physical activity and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2006; 16(1):36-42. DOI: 10.1158/1055-9965.EPI-06-0582. View

Longnecker M . Re: "Point/counterpoint: meta-analysis of observational studies". Am J Epidemiol. 1995; 142(7):779-82. DOI: 10.1093/oxfordjournals.aje.a117710. View

10.

Guay M, Dragomir A, Pilon D, Moride Y, Perreault S . Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol Drug Saf. 2006; 16(1):17-27. DOI: 10.1002/pds.1273. View

11.

Ewertz M, Mellemkjaer L, Poulsen A, Friis S, Sorensen H, Pedersen L . Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer. 2005; 92(7):1293-7. PMC: 2361963. DOI: 10.1038/sj.bjc.6602472. View

12.

Banks E, Canfell K, Reeves G . HRT and breast cancer: recent findings in the context of the evidence to date. Womens Health (Lond). 2008; 4(5):427-31. DOI: 10.2217/17455057.4.5.427. View

13.

Bhavnani B, Strickler R . Menopausal hormone therapy. J Obstet Gynaecol Can. 2005; 27(2):137-62. DOI: 10.1016/s1701-2163(16)30186-4. View

14.

Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M . Hormone replacement therapy and breast cancer in former users of oral contraceptives--The Norwegian Women and Cancer study. Int J Cancer. 2007; 121(3):645-8. DOI: 10.1002/ijc.22699. View

15.

Nelson H . Menopause. Lancet. 2008; 371(9614):760-70. DOI: 10.1016/S0140-6736(08)60346-3. View

16.

Li C, Malone K, Porter P, Weiss N, Tang M, Daling J . The relationship between alcohol use and risk of breast cancer by histology and hormone receptor status among women 65-79 years of age. Cancer Epidemiol Biomarkers Prev. 2003; 12(10):1061-6. View

17.

Friedenreich C, Bryant H, Courneya K . Case-control study of lifetime physical activity and breast cancer risk. Am J Epidemiol. 2001; 154(4):336-47. DOI: 10.1093/aje/154.4.336. View

18.

Nelson H, Humphrey L, Nygren P, Teutsch S, Allan J . Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002; 288(7):872-81. DOI: 10.1001/jama.288.7.872. View

19.

Colditz G . Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Res. 2007; 9(4):108. PMC: 2206710. DOI: 10.1186/bcr1736. View

20.

Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M . Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288(1):49-57. DOI: 10.1001/jama.288.1.49. View